| Autor: |
Ortega MA; Department of Medicine and Medical Specialities (CIBEREHD), Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Madrid, Spain.; Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.; Cancer Registry and Pathology Department, Principe de Asturias University Hospital, 28806 Alcala de Henares, Madrid, Spain., Jiménez-Álvarez L; Department of Medicine and Medical Specialities (CIBEREHD), Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Madrid, Spain.; Department of General and Digestive Surgery, General and Digestive Surgery, Principe de Asturias University Hospital, 28806 Alcala de Henares, Madrid, Spain., Fraile-Martinez O; Department of Medicine and Medical Specialities (CIBEREHD), Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Madrid, Spain.; Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain., Garcia-Montero C; Department of Medicine and Medical Specialities (CIBEREHD), Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Madrid, Spain.; Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain., Guijarro LG; Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.; Unit of Biochemistry and Molecular Biology, Department of System Biology (CIBEREHD), University of Alcala, 28801 Alcala de Henares, Madrid, Spain., Pekarek L; Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.; Oncology Service, Guadalajara University Hospital, 19002 Guadalajara, Spain., Barrena-Blázquez S; Department of Medicine and Medical Specialities (CIBEREHD), Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Madrid, Spain.; Department of General and Digestive Surgery, General and Digestive Surgery, Principe de Asturias University Hospital, 28806 Alcala de Henares, Madrid, Spain., Asúnsolo Á; Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.; Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Madrid, Spain.; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, University of New York, New York, NY 10012, USA., López-González L; Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.; Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Madrid, Spain., Toledo-Lobo MDV; Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.; Unit of Cell Biology, Department of Biomedicine and Biotechnology, University of Alcala, 28801 Alcala de Henares, Madrid, Spain., Álvarez-Mon M; Department of Medicine and Medical Specialities (CIBEREHD), Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Madrid, Spain.; Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.; Immune System Diseases-Rheumatology, Oncology Service and Internal Medicine (CIBEREHD), Principe de Asturias University Hospital, 28806 Alcala de Henares, Madrid, Spain., Saez MA; Department of Medicine and Medical Specialities (CIBEREHD), Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Madrid, Spain.; Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.; Pathological Anatomy Service, Central University Hospital of Defence-UAH Madrid, 28801 Alcala de Henares, Madrid, Spain., Gutiérrez-Calvo A; Department of General and Digestive Surgery, General and Digestive Surgery, Principe de Asturias University Hospital, 28806 Alcala de Henares, Madrid, Spain.; Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Madrid, Spain., Díaz-Pedrero R; Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.; Department of General and Digestive Surgery, General and Digestive Surgery, Principe de Asturias University Hospital, 28806 Alcala de Henares, Madrid, Spain.; Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Madrid, Spain. |
| Abstrakt: |
Pancreatic cancer is a type of gastrointestinal tumor with a growing incidence and mortality worldwide. Pancreatic ductal adenocarcinoma (PDAC) constitutes 90% of cases, and late-stage diagnosis is common, leading to a 5-year survival rate of less than 10% in high-income countries. The use of biomarkers has different proven translational applications, facilitating early diagnosis, accurate prognosis and identification of potential therapeutic targets. Several studies have shown a correlation between the tissue expression levels of various molecules, measured through immunohistochemistry (IHC), and survival rates in PDAC. Following the hallmarks of cancer, epigenetic and metabolic reprogramming, together with immune evasion and tumor-promoted inflammation, plays a critical role in cancer initiation and development. In this study, we aim to explore via IHC and Kaplan-Meier analyses the prognostic value of various epigenetic-related markers (histones 3 and 4 (H3/H4), histone acetyl transferase 1 (HAT-1), Anti-Silencing Function 1 protein (ASF1), Nuclear Autoantigenic Sperm Protein (NASP), Retinol Binding Protein 7 (RBBP7), importin 4 (IPO4) and IPO5), metabolic regulators (Phosphoglycerate mutase (PGAM)) and inflammatory mediators (allograft inflammatory factor 1 (AIF-1), interleukin 10 (IL-10), IL-12A and IL-18) in patients with PDAC. Also, through a correlation analysis, we have explored the possible interconnections in the expression levels of these molecules. Our results show that higher expression levels of these molecules are directly associated with poorer survival rates in PDAC patients, except in the case of IL-10, which shows an inverse association with mortality. HAT1 was the molecule more clearly associated with mortality, with a hazard risk of 21.74. The correlogram demonstrates an important correlation between almost all molecules studied (except in the case of IL-18), highlighting potential interactions between these molecules. Overall, our study demonstrates the relevance of including different markers from IHC techniques in order to identify unexplored molecules to develop more accurate prognosis methods and possible targeted therapies. Additionally, our correlation analysis reveals potential interactions among these markers, offering insights into PDAC's pathogenesis and paving the way for targeted therapies tailored to individual patient profiles. Future studies should be conducted to confirm the prognostic value of these components in PDAC in a broader sample size, as well as to evaluate the possible biological networks connecting them. |
